Skip to main content
. 2008 Jun 23;105(26):9017–9022. doi: 10.1073/pnas.0710445105

Fig. 4.

Fig. 4.

TNFα and IL-1β production of PBMC bearing Nod1ins/del or Nod2fs mutation. PBMC were exposed either to a dose range of SCW fragments or to ultrapure TLR2 or TLR4 agonists for 24 h. As positive controls, muramyl-tri-DAP (MTP) and MDP were used. (A and B) TNFα or IL-1β production in control and Nod1ins/del bearing PBMC. (C and D) TNFα and IL-1β production in Nod2fs carrying PBMC. Data represent the mean ± SD of four controls and four frameshift mutations. *, P < 0.05, Mann–Whitney U test, compared with wild-type control.